tbuckley/cabot-search huggingface dataset:
The cell membrane repair protein MG53 modulates transcription factor NF-κB signaling to control kidney fibrosis
Authors: Haichang Li, Pu Duann, Zhongguang Li, Xinyu Zhou, Jianjie Ma, Brad H. Rovin, Pei-Hui Lin
Journal: Kidney International (2021)

Kidney fibrosis is associated with the progression of acute kidney injury to chronic kidney disease. MG53, a cell membrane repair protein, has been shown to protect against injury to kidney epithelial cells and acute kidney injury. Here, we evaluated the role of MG53 in modulation of kidney fibrosis in aging mice and in mice with unilateral ureteral obstruction (UUO) a known model of progressive kidney fibrosis. Mice with ablation of MG53 developed more interstitial fibrosis with age than MG53-intact mice of the same age. Similarly, in the absence of MG53, kidney fibrosis was exaggerated compared to mice with intact MG53 in the obstructed kidney compared to the contralateral unobstructed kidney or the kidneys of sham operated mice. The ureteral obstructed kidneys from MG53 deficient mice also showed significantly more inflammation than ureteral obstructed kidneys from MG53 intact mice. In vitro experiments demonstrated that MG53 could enter the nuclei of proximal tubular epithelial cells and directly interact with the p65 component of transcription factor NF-κB, providing a possible explanation of enhanced inflammation in the absence of MG53. To test this, enhanced MG53 expression through engineered cells or direct recombinant protein delivery was given to mice subject to UUO. This reduced NF-κB activation and inflammation and attenuated kidney fibrosis. Thus, MG53 may have a therapeutic role in treating chronic kidney inflammation and thereby provide protection against fibrosis that leads to the chronic kidney disease phenotype.
Helen Salisbury: Could it be covid?
Authors: Helen Salisbury
Journal: BMJ (2021)

Every year, as the weather turns colder, many patients present to their GP with symptoms of a respiratory virus. All GPs have a well rehearsed explanation about why this three day cough accompanied by a sore throat and runny nose is viral, rather than bacterial, and won’t be helped by antibiotics. The routine has been adjusted this year to include an additional question: “Have you done a covid test?” In most cases the answer is no, which is understandable but also alarming.

The government’s coronavirus website still lists the main symptoms of infection as a high temperature, a …
Next Generation Sequencing (NGS)-Based Post-Transplant Monitoring in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
Authors: Taehyung Kim, Joon Ho Moon, Jae-Sook Ahn, Marc S. Tyndel, Yeo-Kyeoung Kim, Seung-Shin Lee, Seo-Yeon Ahn, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Seunghyun Choi, Myung-Geun Shin, Hoon Kook, Sun-Hee Kim, Seong Kyu Park, Hyeoung-Joon Kim, Zhaolei Zhang, Dennis Kim
Journal: Blood (2017)
Women with kidney disease can be given a personal risk assessment for pregnancy
Authors: Helen Saul, Deniz Gursul
Journal: BMJ (2021)

The studyWiles K, Webster P, Seed PT, et al. The impact of chronic kidney disease Stages 3-5 on pregnancy outcomes. Nephrol Dial Transplant 2020;gfaa247.To read the full NIHR Alert go to: https://evidence.nihr.ac.uk/alert/women-kidney-disease-given-risk-assessment-pregnancy/.
TCT-299 Association of Frailty With Treatment Selection and Long-Term Outcomes Among Patients With Chronic Limb-Threatening Ischemia
Authors: Neel Butala, Aishwarya Raja, Jiaman Xu, Jordan Strom, Marc Schermerhorn, Joshua Beckman, Mehdi Shishehbor, Robert Yeh, Eric Secemsky
Journal: Journal of the American College of Cardiology (2021)
Long-term Health and Social Outcomes in Children and Adolescents Placed in Out-of-Home Care
Authors: Amir Sariaslan, Antti Kääriälä, Joonas Pitkänen, Hanna Remes, Mikko Aaltonen, Heikki Hiilamo, Pekka Martikainen, Seena Fazel
Journal: JAMA Pediatrics (2021)

Children who are placed in out-of-home care may have poorer outcomes in adulthood, on average, compared with their peers, but the direction and magnitude of these associations need clarification.To estimate associations between being placed in out-of-home care in childhood and adolescence and subsequent risks of experiencing a wide range of social and health outcomes in adulthood following comprehensive adjustments for preplacement factors.This cohort and cosibling study of all children born in Finland between 1986 and 2000 (N = 855 622) monitored each person from their 15th birthday either until the end of the study period (December 2018) or until they migrated, died, or experienced the outcome of interest. Cox and Poisson regression models were used to estimate associations with adjustment for measured confounders (from linked population registers) and unmeasured familial confounders (using sibling comparisons). Data were analyzed from October 2020 to August 2021.Placement in out-of-home care up to age 15 years.Through national population, patient, prescription drug, cause of death, and crime registers, 16 specific outcomes were identified across the following categories: psychiatric disorders; low socioeconomic status; injuries and experiencing violence; and antisocial behaviors, suicidality, and premature mortality.A total of 30 127 individuals (3.4%) were identified who had been placed in out-of-home care for a median (interquartile range) period of 1.3 (0.2-5.1) years and 2 (1-3) placement episodes before age 15 years. Compared with their siblings, individuals who had been placed in out-of-home care were 1.4 to 5 times more likely to experience adverse outcomes in adulthood (adjusted hazard ratio [aHR] for those with a fall-related injury, 1.40; 95% CI, 1.25-1.57 and aHR for those with an unintentional poisoning injury, 4.79; 95% CI, 3.56-6.43, respectively). The highest relative risks were observed for those with violent crime arrests (aHR, 4.16; 95% CI, 3.74-4.62; cumulative incidence, 24.6% in individuals who had been placed in out-of-home care vs 5.1% in those who had not), substance misuse (aHR, 4.75; 95% CI, 4.25-5.30; cumulative incidence, 23.2% vs 4.6%), and unintentional poisoning injury (aHR 4.79; 95% CI, 3.56-6.43; cumulative incidence, 3.1% vs 0.6%). Additional adjustments for perinatal factors, childhood behavioral problems, and traumatic injuries, including experiencing violence, did not materially change the findings.Out-of-home care placement was associated with a wide range of adverse outcomes in adulthood, which persisted following adjustments for measured preplacement factors and unmeasured familial factors.
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer
Authors: Ryon P. Graf, Virginia Fisher, Joaquin Mateo, Ole V. Gjoerup, Russell W. Madison, Kira Raskina, Hanna Tukachinsky, James Creeden, Rachel Cunningham, Richard S.P. Huang, Douglas A. Mata, Jeffrey S. Ross, Geoffrey R. Oxnard, Jeffrey M. Venstrom, Amado J. Zurita
Journal: European Urology (2021)

Biomarkers predicting second-generation novel hormonal therapy (NHT) benefit relative to taxanes are critical for optimized treatment decisions for metastatic castration-resistant prostate cancer (mCRPC) patients. These associations have not been reported simultaneously for common mCRPC genomic biomarkers.To evaluate predictive associations of common genomic aberrations in mCRPC using an established comprehensive genomic profiling (CGP) system.A retrospective cohort study used data from a deidentified US-based clinicogenomic database comprising patients treated in routine clinical practice between 2011 and 2020, evaluated with Foundation Medicine CGP in tissue biopsies obtained around the time of treatment decision. The main cohort included 180 NHT and 179 taxane lines of therapy (LOTs) from 308 unique patients. The sequential cohort comprised a subset of the main cohort NHT LOTs immediately followed by taxane from 55 unique patients.Prostate-specific antigen (PSA) response, time to next treatment (TTNT), and overall survival (OS) were assessed. Main cohort analyses were adjusted for known treatment assignment biases via inverse probability of treatment weighting (IPTW) in treatment interaction models.In the main cohort, patients with AR amplification (ARamp) or PTEN aberrations (PTENalt) had worse relative PSA response on NHT versus taxanes compared with patients without. Patients with ARamp, PTENalt, or RB1 aberrations (RB1alt) also had worse relative TTNT and OS on NHT but not on taxanes. In multivariable models for TTNT and OS adjusted via IPTW, ARamp, PTENalt, and RB1alt were shown as poor prognostic factors overall and demonstrated significant treatment interactions, indicating reduced hazards of therapy switch and death on taxanes versus NHT. Consistent associations favoring increased benefit from subsequent taxane despite prior NHT treatment line were observed only for ARamp in the sequential cohort, in which very few patients had RB1alt for assessment.ARamp status is a candidate biomarker to predict poor effectiveness of NHT relative to taxanes in mCRPC in scenarios where both options are considered.Specific alterations in the DNA of tumors may assist in choosing between novel oral hormonal therapies and standard chemotherapy in advanced prostate cancer patients.
TCT-64 Racial Differences and In-Hospital Mortality Associated With Stress-Induced Cardiomyopathy During the COVID-19 Pandemic
Authors: Banveet Kaur Khetarpal, Awad Javaid, Christoph Sossou, Ariyon Schreiber, Chowdhury Ahsan, Komandoor Srivathsan
Journal: Journal of the American College of Cardiology (2021)
Greenness Surrounding Schools and Visual Impairment in Chinese Children and Adolescents
Authors: Bo-Yi Yang, Shanshan Li, Zhiyong Zou, Iana Markevych, Joachim Heinrich, Michael S. Bloom, Ya-Na Luo, Wen-Zhong Huang, Xiang Xiao, Zhaohuan Gui, Wen-Wen Bao, Jin Jing, Jun Ma, Yinghua Ma, Yajun Chen, Guang-Hui Dong
Journal: Environmental Health Perspectives (2021)

Evidence concerning the effects of greenness on childhood visual impairment is scarce.We aimed to assess whether greenness surrounding schools was associated with visual impairment prevalence and visual acuity levels in Chinese schoolchildren and whether the associations might be explained by reduced air pollution.In September 2013, we recruited 61,995 children and adolescents 6-18 years of age from 94 schools in seven provinces/municipalities in China. Greenness exposure was assessed using the normalized difference vegetation index (NDVI) and the soil-adjusted vegetation index (SAVI) from July to August 2013. Visual impairment was defined as at least one visual acuity level (dimensionless) lower than 4.9 (Snellen 5/6 equivalent). Three-year annual averages of particulate matter (PM) with an aerodynamic diameter of ≤1μm (PM1) and nitrogen dioxide (NO2) at each school were assessed using machine learning methods. We used generalized linear mixed models to estimate the associations between greenness and prevalent visual impairment and visual acuity levels and used mediation analyses to explore the potential mediating role of air pollution.In the adjusted model, an interquartile range increase in NDVI500m was associated with lower odds of prevalent visual impairment [odds ratio (OR)=0.95; 95% confidence interval (CI): 0.93, 0.97]. The same increase in NDVI500m was also associated with 0.012 (95% CI: 0.008, 0.015) and 0.011 (95% CI: 0.007, 0.015) increases in visual acuity levels for left- and right-eye, respectively. Our results also suggested that PM1 and NO2 significantly mediated the association between NDVI500m and visual impairment. Similar effect estimates were observed for SAVI500m, and our estimates were generally robust in several sensitivity analyses.These findings suggest higher greenness surrounding schools might reduce the risk of visual impairment, possibly owing in part to lower PM1 and NO2 in vegetated areas. Further longitudinal studies with more precise greenness assessment are warranted to confirm these findings. https://doi.org/10.1289/EHP8429.
Lumbosacral Plexus Neurolymphomatosis: A Typical 18FDG PET/CT Pattern to Recognize.
Authors: Karl Bordeau, Marie-Claude Eberlé, Michel Fabbro, Cyril Fersing, Emmanuel Deshayes
Journal: Clinical Nuclear Medicine (2021)

ABSTRACT A 79-year-old man anteriorly treated for primary central nervous system diffuse large B-cell lymphoma with MRI complete response after immunochemotherapy was referred 1 year later for 18FDG PET/CT because of right persistent lombosciatic radicular pain for 6 months with negative medullary and spine MRI and negative cerebrospinal fluid cytology. Linearly intense uptake was observed in several roots of lumbosacral plexus, highly suggestive of peripheral neurolymphomatosis relapse. No specific treatment was engaged because of rapid decrease of performance status leading to death.
Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non–Small Cell Lung Cancer
Authors: Lu Tian, Bo Huang, Lee-Jen Wei
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Long non-coding RNA NORAD interaction with miR-346 impacts DNA damage response and anti-tumor immunity in prostate cancer.
Authors: C Fletcher, L Deng, F Orafidiya, W Yuan, I Figueiredo, B Gurel, D Leach, F Issa, A Neeb, D Bogdan, F Dobbs, Y Philippou, E A Murphy, S G Zhao, J Hester, R J Bryant, S H Reed, K E Knudsen, I G Mills, J de Bono, C L Bevan
Journal: Cancer Research (2021)
Abstract 14791: Mitral Annular Calcification is Not Associated With Survival After Percutaneous Edge-to-Edge Repair of Mitral Regurgitation
Authors: Emily Tat, Richard Cheng, Reza Arsanjani, Robert J Siegel, Asma Hussaini, Alfredo Trento, Saibal Kar
Journal: Circulation (2015)

Introduction: Mitral annular calcification (MAC) has been associated with age, hemodialysis (HD) status, coronary disease, and mortality. While MAC is seen frequently in pts undergoing percutaneous edge-to-edge repair of mitral regurgitation (MR) its impact on survival is unknown. Hypothesis: MAC is not associated with mortality after percutaneous MR repair. Methods: Pts who underwent MitraClip repair of MR between Apr 2009 and May 2014 were included. Kaplan-Meier survival was plotted between pts with no MAC and pts with MAC. A multivariate Cox regression of all-cause mortality was performed simultaneously adjusting for MAC, age, HD status, and prior myocardial infarction (MI). Results: 173 pts were included. Mean age at percutaneous repair was 76.9 ± 12.6 yrs and 40.8% were females. MAC was present in 86/173 (49.7%) of pts, and was mild in 61/86 (70.9%) cases and moderate or severe in the remaining cases. In pts with MAC prevalence of prior MI was higher 28/86 (32.6%) vs. 16/87 (18.4%) p=0.037 but ejection fraction was similar 51.8 ± 17.1 vs. 50.4 ± 18.6 % p=0.603. Age was increased in pts with MAC 79.9 ± 10.1 vs. 74.3 ± 14.0 yrs p=0.003. MR was moderate-to-severe in 35/173 (20.2%) of pts and severe in 138/173 (79.8%) of pts. MR improved by 2 grades or more in 165/173 (95.4%) of pts after repair. Survival was decreased in pts with MAC as compared to pts with no MAC by Log Rank p=0.049 (Figure 1A). However, in a multivariate Cox regression model of all-cause mortality, MAC, after adjusting for age, HD status, and prior MI, was not associated with mortality with a hazard ratio of 1.166 (95% CI 0.707 - 1.922) p=0.548 (Figure 1B). In this model age and prior MI were associated with mortality with hazard ratios of 1.048 (95% CI 1.021 - 1.077) p=0.001 and 1.798 (95% CI 1.052 - 3.075) p=0.032, respectively. Conclusions: The presence of MAC was not associated with mortality after adjusting for age, HD status, and prior MI and should not preclude the MitraClip procedure. Procedural success was equally high.
TCT-177 Direct Oral Anticoagulants Versus Vitamin K Antagonist After Transcatheter Aortic Valve Replacement in Patients With Concomitant Indication for Oral Anticoagulation: A Meta-Analysis
Authors: Wasawat Vutthikraivit, Pattara Rattanawong, Prapaipan Putthapiban, Jakrin Kewcharoen
Journal: Journal of the American College of Cardiology (2021)
KS-356, a novel inhibitor of TGF-beta superfamily signaling, improves obesity and obesity-related hepatic steatosis by inhibition of TGF-beta/Smad3 signaling pathway in high-fat diet-induced mice
Authors: Kisoo Pahk, Sang Gil Lee, Chanmin Joung, Sungeun Kim, Sang Geon Kim, Won-Ki Kim
Journal: Journal of Hepatology (2021)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
Authors: Laura C Coates, Laure Gossec, Elke Theander, Paul Bergmans, Marlies Neuhold, Chetan S Karyekar, May Shawi, Wim Noël, Georg Schett, Iain B McInnes
Journal: Annals of the Rheumatic Diseases (2021)

Objective To evaluate efficacy and safety of guselkumab, an anti-interleukin-23p19-subunit antibody, in patients with psoriatic arthritis (PsA) with prior inadequate response (IR) to tumour necrosis factor inhibitors (TNFi). Methods Adults with active PsA (≥3 swollen and ≥3 tender joints) who discontinued ≤2 TNFi due to IR (lack of efficacy or intolerance) were randomised (2:1) to subcutaneous guselkumab 100 mg or placebo at week 0, week 4, then every 8 weeks (Q8W) through week 44. Patients receiving placebo crossed over to guselkumab at week 24. The primary (ACR20) and key secondary (change in HAQ-DI, ACR50, change in SF-36 PCS and PASI100) endpoints, at week 24, underwent fixed-sequence testing (two-sided α=0.05). Adverse events (AEs) were assessed through week 56. Results Among 285 participants (female (52%), one (88%) or two (12%) prior TNFi), 88% of 189 guselkumab and 86% of 96 placebo→guselkumab patients completed study agent through week 44. A statistically significantly higher proportion of patients receiving guselkumab (44.4%) than placebo (19.8%) achieved ACR20 (%difference (95% CI): 24.6 (14.1 to 35.2); multiplicity-adjusted p&lt;0.001) at week 24. Guselkumab was superior to placebo for each key secondary endpoint (multiplicity-adjusted p&lt;0.01). ACR20 response (non-responder imputation) in the guselkumab group was 58% at week 48; &gt;80% of week 24 responders maintained response at week 48. Through week 24, serious AEs/serious infections occurred in 3.7%/0.5% of 189 guselkumab-randomised and 3.1%/0% of 96 placebo-randomised patients; the guselkumab safety profile was similar through week 56, with no deaths or opportunistic infections. Conclusion Guselkumab significantly improved joint and skin manifestations and physical function in patients with TNFi-IR PsA. A favourable benefit–risk profile was demonstrated through 1 year. Trial registration number NCT03796858 .
TCT-119 Association Among Degree of Coronary Artery Calcification, Clinical Presentation, and Adverse Clinical Outcomes After PCI: A Patient-Level Pooled Analysis of 11 Randomized Trials
Authors: Mahesh Madhavan, Keyvan Karimi Galougahi, Bjorn Redfors, Yousif Ahmad, Megha Prasad, Philippe Genereux, Akiko Maehara, Zhipeng Zhou, Ori Ben-Yehuda, Clemens von Birgelen, Pieter Smits, Roxana Mehran, Ziad Ali, Patrick Serruys, Ajay Kirtane, Martin Leon, Gregg Stone
Journal: Journal of the American College of Cardiology (2021)
Stigma-Reducing Clinician Training to Improve Primary Clinical Care
Authors: Karina W. Davidson
Journal: JAMA Network Open (2021)

Brandon A. Kohrt, MD, PhD; Mark J. D. Jordans, PhD; Elizabeth L. Turner, PhD; Sauharda Rai, MA; Dristy Gurung, MSc; Manoj Dhakal, MA; Anvita Bhardwaj, MSPH; Jagannath Lamichhane, MSc; Daisy R. Singla, PhD; Crick Lund, PhD; Vikram Patel, MD, PhD; Nagendra P. Luitel, MPhil; Kathleen J. Sikkema, PhD
TCT-391 Left Atrial Appendage Thrombus and Cerebrovascular Events Post-TAVR
Authors: Maarten van Wiechen, Marguerite Faure, Thijmen Hokken, Joris Ooms, Marjo De Ronde, Alexander Hirsch, Joost Daemen, Peter de Jaegere, Ricardo Budde, Nicolas Van Mieghem
Journal: Journal of the American College of Cardiology (2021)
Dual-Phase 18F-Florbetaben PET/CT: Unsuspected Thalamic Infarction Mimicking Alzheimer Disease.
Authors: Teodoro Rudolphi-Solero, Eva María Triviño Ibáñez, Tarik Aroui, Rocío Hervás Navidad, Manuel Gómez-Río
Journal: Clinical Nuclear Medicine (2021)

ABSTRACT Dual-phase amyloid PET is considered a useful protocol to study patients with cognitive impairment. Early-phase 18F-florbetaben PET/CT has been proposed as a surrogate of 18F-FDG PET/CT providing information related to regional brain perfusion. We report the case of a 61-year-old woman referred to the cognitive impairment unit for study, preliminary diagnosed as probable Alzheimer disease. The dual-phase 18F-florbetaben PET/CT was shown as the main finding, no uptake in the left anterior thalamus. Memory and language symptoms have been described as primary clinical features of anterior thalamic infarctions that could be confused with the main manifestations of Alzheimer disease.
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
Authors: Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J. Lee, Karen Yee, Andrew Dalovisio, Eunice S. Wang, Juan M. Bergua Burgues, Jeffrey Schriber, Mark R. Litzow, Olga Frankfurt, Teresa Bernal Del Castillo, Vijaya Raj Bhatt, Bhavana Bhatnagar, Priyanka Mehta, Richard Dillon, Maria Vidriales Vicente, Stephen Anthony, David Bearss, Pau Montesinos, B. Douglas Smith
Journal: Blood Cancer Journal (2021)

A prospective biomarker analysis of alvocidib followed by cytarabine
Options to Minimize the Use of Central Lines: Midodrine, Peripheral Venous Lines, and Midline Catheters
Authors: Rania Farhat, Jennifer Minoff, Shannon Burke, Setu Patolia
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

"Options to Minimize the Use of Central Lines: Midodrine, Peripheral Venous Lines, and Midline Catheters." American Journal of Respiratory and Critical Care Medicine, 204(12), pp. 1473–1475
Abstract 13921: Coronary Graft Perforation Complicating Percutaneous Coronary Intervention With Excimer Laser Coronary Atherectomy in a Patient With Saphenous Vein Graft Occlusion
Authors: Yuvraj S Chowdhury, Mrinali Shetty, Radhika-Alicia Patel, Pratik Patel
Journal: Circulation (2019)

Introduction: There is limited data on coronary perforation occurring during percutaneous coronary intervention (PCI) in patients with a history of coronary artery bypass surgery (CABG) with an inc...
Retraction notice to “Phototherapy together with it triggered immunological response for Anti-HPV treatment of oropharyngeal cancer: Removing tumor and pathogenic virus simultaneously” [Biomaterials (2021) 120777]
Authors: Zhao Liu, Xinxin Yang, Ruiqi Liu, Junjie Bao, Na An, Shan Jiang, Susheng Miao, Chongshen Guo, Guofan Qu, Hongxue Meng
Journal: Biomaterials (2021)